Impact of Palliative Care Clinical Pharmacists in an Inpatient Care Setting on Total Health Care Expenditures.

Inpatient palliative care clinical pharmacy specialists (IPCPS) on multidisciplinary palliative care (PC) teams have expanding roles in the treatment of pain, nausea, and other symptoms for patients with serious illnesses. The aim of this study was to assess the clinical and financial outcomes associated with an IPCPS on an inpatient PC team. This was a retrospective cohort study conducted in Colorado. Adult patients with an inpatient stay and a PC consult between October 1, 2016 and February 28, 2019 were included. Patients were assigned to the observation group if they received PC from a clinical pharmacist and control group if they received usual PC. The primary outcome was the 180-day change in daily total cost-of-care expenditures. Secondary outcomes included length of index hospitalization and 180-day change in daily morphine milligram equivalents (MME), health care utilization, and opioid adverse effects (AE). A total of 1543 patients were included with 228 and 1315 in the IPCPS and usual care groups, respectively. After adjustment, the IPCPS group had a greater median decrease in daily expenditures (-$22 vs. $6,  = 0.003), higher median increase in daily MME (16.5 vs. 9.7 mg,  = 0.007), and fewer patients with a subsequent hospitalization (34.2% vs. 39.2%,  = 0.010) or urgent care visit (10.5% vs. 14.6%,  = 0.024) but longer mean index hospitalization (9.3 vs. 7.7 days,  = 0.003) and no differences in AE during follow-up (all  > 0.05). IPCPS participation on the PC team can be a component of health care cost reduction while contributing to patient-centered quality care.